Product Information
SERTRALINE 150 MG CAPSULE is a generic product labeled by Alvogen Inc., priced at $1.2507 per EA under NDC 47781095130. Its NADAC has been published 49 times since Oct 29, 2025.
FDA first approved this application on Oct 4, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Alvogen Inc.NDC
47781095130
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SERTRALINE HYDROCHLORIDEApproval Type
Authorized Generic (NDA)
FDA Application
NDA215133FDA Approved
10/4/2021
TE Code
AB
On Market Since
9/18/2025
Pharmacological Classes
Price Statistics
The NADAC for SERTRALINE 150 MG CAPSULE has been published 49 times since Oct 29, 2025, and over the history we have for it it has declined 75.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.2507 per EA |
|---|---|
| All-time high | $5.1702 (Nov 12, 2025) |
| All-time low | $1.2507 (Sep 23, 2026) |
| 52-week high | $5.1702 |
| 52-week low | $1.2507 |
| Median price | $4.7220 |
| Average price | $3.7792 |
| Largest weekly change | -33.8% (Jul 22, 2026) |
| Weeks tracked | 49 |
| Tracking since | Oct 29, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Alvogen Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
sertraline hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SERTRALINE 150 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for SERTRALINE 150 MG CAPSULE, manufactured by Alvogen Inc., is $1.2507 per EA (NDC 47781095130), effective Sep 30, 2026.
How has the price of SERTRALINE 150 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for SERTRALINE 150 MG CAPSULE has declined 75.8%. It has been tracked across 49 weekly CMS publications since Oct 29, 2025.
What are the highest and lowest recorded NADAC prices for SERTRALINE 150 MG CAPSULE?
Since Oct 29, 2025, the NADAC for SERTRALINE 150 MG CAPSULE has ranged from a low of $1.2507 (Sep 23, 2026) to a high of $5.1702 (Nov 12, 2025), with a median of $4.7220 per EA.
Are there cheaper alternatives to SERTRALINE 150 MG CAPSULE?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as SERTRALINE 150 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures SERTRALINE 150 MG CAPSULE?
SERTRALINE 150 MG CAPSULE (NDC 47781095130) is labeled by Alvogen Inc., and CMS classifies it as a generic product.